Quidditas Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Quidditas Therapeutics is an early-stage biotech pioneering a new genome editing platform termed GREAT (Genetic Recombination Editing Technology). The technology is designed for targeted and controlled excision and recombination of nucleic acids, claiming broader application scope and improved standardization compared to existing tools. Founded in 2021 and headquartered in Leuven's biotech hub, the company recently raised €2.62 million in May 2025 to accelerate development. Its primary focus is on creating a new generation of treatments for genetic disorders, while also exploring partnerships in other fields like oncology, organ transplant, and industrial bioprocessing.

NeuroscienceRare Disease

Technology Platform

GREAT (Genetic Recombination Editing Technology) - A proprietary genome editing platform enabling targeted and controlled excision and absolute genetic recombination of nucleic acids from any source, anywhere in the genome. Claims broader application scope and improved standardization over existing tools.

Opportunities

The company operates in the rapidly growing genome editing market, with a platform that claims broader applicability than current standards.

Its focus on genetic disorders addresses a high-unmet-need area with potential for transformative therapies.

The platform's potential in non-therapeutic fields (bioprocessing, food industry) offers additional partnership and revenue avenues.

Risk Factors

The novel GREAT technology faces unproven technical and safety validation against established, evolving competitors like CRISPR.

As a pre-revenue company, it is dependent on future fundraising in a competitive capital environment.

Translational challenges, particularly in vivo delivery for neurological targets, present significant hurdles to therapeutic development.

Competitive Landscape

Quidditas competes in the intensely competitive genome editing arena against well-funded leaders like CRISPR Therapeutics, Intellia, and Beam, as well as numerous academic and startup groups developing novel editors (e.g., base editors, prime editors, transposases). Its success hinges on demonstrating clear, defensible advantages in precision, efficiency, delivery, or scope over these established and emerging technologies.

More companies in CRISPR / Gene Editing →More companies in Belgium →